Ragifilimab

DB18853InvestigationalProtein Based Therapies

Ragifilimab is under investigation in clinical trial NCT04225039 (Anti-gitr/anti-pd1/stereotactic Radiosurgery, in Recurrent Glioblastoma).

Mechanism
Curator reviewed
Also known as
Anti-gitr agonistic monoclonal antibody incagn01876 · Immunoglobulin g1 (de-448-lysine), anti-(human tumor necrosis factor receptor tnfrsf18) (human-mus musculus monoclonal incagn01876.gamma.1-chain), disulfide with human-mus musculus monoclonal incagn01876 .kappa.-chain, dimer · Incagn-01876 · Incagn01876
Code names
AGEN-1876 · CM-701

Resolves to

Compound
UNIIO440IW9NHNCAS2207590-51-8
Targets
Q9Y5U5TNFRSF18

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ragifilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In